Safety and efficacy of antithrombotics in outpatients with symptomatic COVID-19 : A systematic review and meta-analysis
Copyright © 2024 Elsevier Inc. All rights reserved..
BACKGROUND: Coronavirus disease (COVID-19) is a global health emergency, with well over six hundred million infections and over six million deaths to date. Besides other ramifications, it is also associated with inflammation and an augmented risk of thromboembolic complications. Despite this, the risks and benefits of antithrombotic drugs in patients with mild to moderate COVID-19 have not been well-established and remain controversial.
OBJECTIVES: To evaluate the safety and efficacy of antithrombotic drugs on mild to moderate symptomatic COVID-19 patients by performing an updated systematic review and meta-analysis.
METHODS: We queried electronic databases (PubMed, Cochrane Central, Scopus, and Embase) from their inception up to September 2022 for randomized controlled trials comparing antithrombotic drugs against placebo. The outcomes of interest were the need for hospital care, mortality, and thromboembolic events in the enrolled participants. Dichotomous outcomes were presented as risk ratio (RR) with 95 % confidence intervals (CIs) and were consolidated using random-effects model.
MAIN RESULTS: Five eligible studies (Rivaroxaban/Apixaban, two; enoxaparin, two; Sulodexide, one), consisting of 2,005 participants with mild to moderate COVID-19, were included. Pooled results show that antithrombotics, when compared to placebo, do not significantly reduce all-cause mortality (RR 0.51, 95 % CI 0.15-1.68; P = 0.27; I2 = 0), thromboembolic events (RR 0.78, 95 % CI 0.17-3.51; P = 0.74; I2 = 0), need for hospitalization (RR 0.73, 95 % CI 0.51-1.03; P = 0.08; I2 = 0), nor significantly increase clinically relevant non-major bleeding events (RR 2.36, 95 % CI 0.56-9.89; P = 0.24; I2 = 0). However, when Sulodexide was compared independently to other antithrombotics, it significantly reduced the need for hospitalization (RR 0.60, 95 % CI 0.37-0.95; P = 0.03).
CONCLUSIONS: Our pooled analysis was not able to establish statistically significant benefits or risks of using antithrombotic drugs in mild to moderate COVID-19 patients. To further improve our understanding of the efficacy, safety and risk profile of such a therapy, large sample randomized clinical trials are required on a wide scale.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Current problems in cardiology - 49(2024), 4 vom: 15. März, Seite 102451 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ansari, Saad Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antithrombotic drugs |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cpcardiol.2024.102451 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368367398 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368367398 | ||
| 003 | DE-627 | ||
| 005 | 20240304232510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cpcardiol.2024.102451 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM368367398 | ||
| 035 | |a (NLM)38346606 | ||
| 035 | |a (PII)S0146-2806(24)00090-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ansari, Saad Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and efficacy of antithrombotics in outpatients with symptomatic COVID-19 |b A systematic review and meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Coronavirus disease (COVID-19) is a global health emergency, with well over six hundred million infections and over six million deaths to date. Besides other ramifications, it is also associated with inflammation and an augmented risk of thromboembolic complications. Despite this, the risks and benefits of antithrombotic drugs in patients with mild to moderate COVID-19 have not been well-established and remain controversial | ||
| 520 | |a OBJECTIVES: To evaluate the safety and efficacy of antithrombotic drugs on mild to moderate symptomatic COVID-19 patients by performing an updated systematic review and meta-analysis | ||
| 520 | |a METHODS: We queried electronic databases (PubMed, Cochrane Central, Scopus, and Embase) from their inception up to September 2022 for randomized controlled trials comparing antithrombotic drugs against placebo. The outcomes of interest were the need for hospital care, mortality, and thromboembolic events in the enrolled participants. Dichotomous outcomes were presented as risk ratio (RR) with 95 % confidence intervals (CIs) and were consolidated using random-effects model | ||
| 520 | |a MAIN RESULTS: Five eligible studies (Rivaroxaban/Apixaban, two; enoxaparin, two; Sulodexide, one), consisting of 2,005 participants with mild to moderate COVID-19, were included. Pooled results show that antithrombotics, when compared to placebo, do not significantly reduce all-cause mortality (RR 0.51, 95 % CI 0.15-1.68; P = 0.27; I2 = 0), thromboembolic events (RR 0.78, 95 % CI 0.17-3.51; P = 0.74; I2 = 0), need for hospitalization (RR 0.73, 95 % CI 0.51-1.03; P = 0.08; I2 = 0), nor significantly increase clinically relevant non-major bleeding events (RR 2.36, 95 % CI 0.56-9.89; P = 0.24; I2 = 0). However, when Sulodexide was compared independently to other antithrombotics, it significantly reduced the need for hospitalization (RR 0.60, 95 % CI 0.37-0.95; P = 0.03) | ||
| 520 | |a CONCLUSIONS: Our pooled analysis was not able to establish statistically significant benefits or risks of using antithrombotic drugs in mild to moderate COVID-19 patients. To further improve our understanding of the efficacy, safety and risk profile of such a therapy, large sample randomized clinical trials are required on a wide scale | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antithrombotic drugs | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Outpatients | |
| 650 | 4 | |a Systematic review | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Merza, Nooraldin |e verfasserin |4 aut | |
| 700 | 1 | |a Salman, Madiha |e verfasserin |4 aut | |
| 700 | 1 | |a Raja, Adarsh |e verfasserin |4 aut | |
| 700 | 1 | |a Sayeed, Bushra Zafar |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Hafsah Alim Ur |e verfasserin |4 aut | |
| 700 | 1 | |a Bhimani, Sunaina |e verfasserin |4 aut | |
| 700 | 1 | |a Shaikh, Afrah Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Naqi, Unaiza |e verfasserin |4 aut | |
| 700 | 1 | |a Farooqui, Areeba |e verfasserin |4 aut | |
| 700 | 1 | |a Afridi, Simra |e verfasserin |4 aut | |
| 700 | 1 | |a Feroze, Ahsan |e verfasserin |4 aut | |
| 700 | 1 | |a Hameed, Ishaque |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current problems in cardiology |d 1993 |g 49(2024), 4 vom: 15. März, Seite 102451 |w (DE-627)NLM000219622 |x 1535-6280 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2024 |g number:4 |g day:15 |g month:03 |g pages:102451 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cpcardiol.2024.102451 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2024 |e 4 |b 15 |c 03 |h 102451 | ||